Abstract
According to rough estimates, one in every 125 newborns born in the United States has a congenital cardiac abnormality that must be repaired. With the recent development of new biomaterials and innovative treatment methods, percutaneous cardiac valve replacement has been considered as an alternative to surgical procedures. While percutaneous heart valve replacement is a relatively new procedure with a few commercially available devices, the devices are not sufficiently low-profile, and do not grow with the child. To address this issue, a novel low-profile growing percutaneous pediatric heart valve frame made of two types of unique metallic biomaterials (supere lastic nitinol and biodegradable iron) has been developed through this study. The developed pediatric heart valve frame has an innovative mechanism that will expand its diameter by disconnecting biodegradable metals, enabling the growth of the device with the surrounding tissue in the cardiac space. The thermally treated iron wires show stable and gradual degradation characteristics, showing approximately 7.66% for both wires treated under 350 and 450 °C. Polymer-coated wires show a degradation range of 4.96 to 5.55% depending on the type of coating. Degradation test results show the predicted 9–23 months of degradation depending on the type of surface treatment (e.g., thermal treatment, polymer coating), which is a suitable range when compared with the theoretical arterial vessel remodeling process period in the human vascular system. Radial forces calculated by finite element analysis and measured by mechanical testing matched well, showing 5–6 N with a 20% diameter reduction considering the deployed valve frame in the heart. Biocompatibility study results demonstrated superior cell viability in thermally treated iron wires after 3 days of cell culture and showed rarely found platelets on the surface after 3-h blood exposure tests. Prototype devices were successfully fabricated using optimized advanced joining processes for dissimilar metallic materials such as nitinol and iron. This study represents the first demonstration of self-expanding and biodegradable percutaneous heart valve frames for pediatric patients that grow with a child.
Funder
Children's Heart Foundation
Pitt Central Resaerch Development Fund
Subject
Materials Chemistry,Surfaces, Coatings and Films,Surfaces and Interfaces
Reference49 articles.
1. Epidemiology of cardiovascular malformations: Prevalence and risk factors;Loffredo;Am. J. Med. Genet.,2000
2. The editor’s roundtable: Cardiac valve surgery;Friedewald;Am. J. Cardiol.,2007
3. Association, A.H. (2004). Heart Disease and Stroke Statistics—2004 Update, American Heart Association.
4. iData Research (2020). Cardiac Surgery Market Size, Share, and COVID-19 Impact Analysis, iData Research.
5. Current developments and future prospects for heart valve replacement therapy;Kidane;J. Biomed. Mater. Res. Part B Appl. Biomater.,2009